Programme De Prévention Et De Gestion Des Maladies Cardiovasculaires

Objectives

Morocco’s 2018–2021 national cardiovascular disease programme seeks to reduce the substantial health, social and economic burden of cardiovascular disease, the country’s leading cause of death, through integrated prevention, early detection, emergency treatment and coordinated long-term care. It covers cardiovascular risk factors, heart and vascular diseases, and cerebrovascular disease including stroke, while aiming to improve territorial equity and reduce avoidable mortality, disability and financial hardship.[1][2][3]

• Prevent and reduce cardiovascular risk before disease develops through population-level action and individual risk management.[4][5]
• Prioritise modifiable risks including tobacco use, unhealthy diet, physical inactivity, hypertension, dyslipidaemia, diabetes, obesity, harmful alcohol use, air pollution and psychosocial stress.[6][7]
• Combine population prevention with clinical follow-up of people at high or very high cardiovascular risk and those with established disease.[8][9]
• Improve emergency management of acute coronary syndromes, stroke, other acute ischaemia and cardiac decompensation through rapid diagnosis, transport, thrombolysis, angioplasty and thrombectomy.[4][10]
• Optimise coordinated patient pathways for ischaemic heart disease, heart failure and other cardiac diseases, neurovascular disease including stroke, and rheumatic valvular disease.[11][12]
• Provide comprehensive chronic, geriatric, rehabilitation and palliative care that addresses medical, psychosocial, educational, family and living-context needs.[13][14]

The programme establishes three strategic orientations: prevent and detect cardiovascular risks early; improve responses to cardiovascular and neurological emergencies and acute episodes; and optimise coordinated care pathways for patients with cardiovascular disease or high cardiovascular risk.[4][15]Its prevention target is a 25% reduction in the prevalence of high cardiovascular risk in the general population by 2025.[5]Associated targets include reducing tobacco prevalence by 15%, insufficient physical activity by 5%, and salt consumption by approximately 15%, reducing acute rheumatic fever incidence, and ensuring that 50% of people aged over 45 attending general practice or primary care receive a validated cardiovascular-risk assessment at least once by 2025.[5]

For acute care, the intended outcome is a 50% reduction by 2025 in one-month mortality from cardiovascular and neurological attacks among people under 70.[10]Proposed service-access results include nationwide access within 24 hours of a patient-triggered alert to coronary angioplasty for acute coronary syndrome and to diagnosis and thrombolysis and/or thrombectomy for ischaemic stroke in specified under-70 populations.[16]For long-term pathways, the plan aims to halve annual mortality and major cardiovascular events among high- and very-high-risk patients, and one-year mortality after a prior non-fatal major event.[16][17]

Patient-centred continuity is a core principle: general practitioners or family doctors are intended to coordinate follow-up, education, self-care support, referral and liaison with specialist and hospital services.[18][12]The programme also recognises that prevention must be multisectoral, combining health education with action involving schools, transport, urban planning, food industry, media, civil society and government.[7][19]

Implementation

Implementation is designed as an evidence-informed, participatory and phased process, building on existing programmes for hypertension, diabetes, acute rheumatic fever, tobacco control, nutrition and healthy lifestyles.[20][21][22]Programme development drew on epidemiological and documentary review, visits and interviews in urban and rural health facilities, and multidisciplinary diagnostic and strategic workshops involving health professionals, Ministry of Health bodies, regional actors, learned societies, insurers, patients and relatives.[20][23][11]

• Strengthen primary healthcare through risk scoring, structured follow-up, care algorithms, reserved non-communicable disease appointments, patient education, essential cardiovascular medicines, electrocardiography and diagnostic equipment.[24][13]
• Deploy integrated cardiovascular-risk management initially through pilot regions and sites, supported by World Health Organization tools, clinical protocols, e-learning, professional training and subsequent national expansion.[25][26][27]
• Develop regional emergency-ischaemia and stroke arrangements with trained staff, electrocardiography and teletransmission, thrombolytic availability, referral procedures, imaging and appropriately located specialised centres.[10][28][29]
• Establish coordinated pathway models, flowcharts, local care networks and referral and counter-referral arrangements across primary, hospital, specialist, rehabilitation and palliative services.[12][30][31]
• Address regional inequalities in specialist staffing, interventional cardiology, neurovascular capacity, equipment, medicine supply, maintenance and access to emergency care.[24][32][33]

Governance is to centre on a programme team within the Ministry of Health, supported by an intersectoral steering committee bringing together ministry directorates, health-insurance organisations, other ministries, partners and scientific societies.[34]The Cardiovascular Diseases Committee is intended to provide an opinion on implementation, while regional directorates coordinate local delivery through meetings, technical support and national reporting.[34]Government-level advocacy and coordination are envisaged where actions require decisions across sectors or ministries.[35][34]

Stakeholder engagement extends to regional and provincial authorities, university and regional hospitals, professional organisations, the National School of Public Health, universities, the National Health Insurance Agency, local authorities, civil society, non-governmental organisations and international partners including the World Health Organization.[29][27][36]Schools, media, community pharmacists, public figures, food-sector actors and families are also identified as contributors to prevention, communication and patient support.[19][37][14]

Public provision is prioritised, but regulated public-private complementarity may be used where public services are persistently incomplete, particularly for specialised or emergency care.[29][34]Such partnerships are intended to operate under state and health-insurance supervision, with time-limited contracts, defined service scope, accessible pricing arrangements, rigorous evaluation and possible sanctions for non-compliance.[38]

Monitoring arrangements include a unified information system linking primary-care and hospital activity, patient records, clinical follow-up and facility monitoring.[33][30]The programme envisages an annual implementation roadmap and dashboard, national reporting on regional implementation, pilot evaluation before scale-up, quality indicators and compliance assessment of contracted providers.[27][36][34]However, the available material does not specify detailed indicator definitions, reporting frequency, data-verification arrangements, evaluation methods or a comprehensive accountability framework.[30][34]

Financing is recognised as necessary for pathway development, regional organisation, staffing, equipment, medicines, training and specialist platforms, and operational measures are to be budgeted.[30][34]The programme calls for favourable government budget decisions, dedicated resources and potential operational or financial contributions from partners, but does not provide a quantified budget, funding allocations, funding gap or costing methodology.[35][38][39]

Monitoring & Evaluation

The programme envisages a national monitoring and evaluation approach combining population risk-factor surveillance, clinical follow-up, service-activity monitoring, implementation dashboards, pilot evaluation and oversight of public-private arrangements. It sets several quantified results targets, but the available material does not define a complete indicator dictionary, consistent reporting timetable, data-verification process or consolidated accountability framework.[4][5][10][30][34]

• Monitor population cardiovascular risk through epidemiological surveys, including assessment of rural-urban, sex-specific and multiple-risk-factor patterns.[6][21]
• Track prevention results against targets to reduce high cardiovascular-risk prevalence by 25% by 2025, tobacco use by 15%, insufficient physical activity by 5%, salt consumption by approximately 15%, and acute rheumatic fever incidence, while ensuring cardiovascular-risk assessment for 50% of people aged over 45 attending primary care or general practice.[5]
• Measure acute-care outcomes through the target to halve one-month mortality from cardiovascular and neurological attacks among people under 70 by 2025, alongside proposed 24-hour access targets for coronary angioplasty and stroke diagnosis and treatment.[10][16]
• Monitor long-term pathway outcomes through targets for compliant medical and educational follow-up for 75% of high-risk patients, individualised care and pathway plans for 50% of diagnosed patients, and explicit personalised support plans for one in two frail primary-care patients.[13][12]
• Establish integrated information systems covering primary healthcare establishments and hospitals, patient records, clinical follow-up, facility activity, chronic-disease monitoring and registries containing management indicators.[33][30][40][41]
• Use an annual implementation roadmap and dashboard, national reporting on regional delivery, regional coordination meetings, and review by the Cardiovascular Diseases Committee.[34]
• Evaluate pilot interventions before national expansion, including high-risk management in three regions, rehabilitation initiatives, pathway models and public-private partnership arrangements.[29][27][36][38]
• Apply compliance assessment to contracted private providers and permit sanctions, including withdrawal from agreements, for non-compliance or misuse of partnership arrangements.[38]
• Review the reliability of cause-of-death reporting and address weaknesses in primary-care and hospital information systems.[42][43][44][40]

Costing & Financing

No overall programme budget, costed workplan, financing envelope, quantified funding gap, unit-cost schedule or economic model is provided. The material nevertheless identifies major financial pressures from household payment, concentration of insurance expenditure among people with long-term conditions, costly specialised services and medicines, and unmet investment needs across the cardiovascular pathway.[2][29][30][39]

• Recognise household financial exposure: direct household payments represented 54% of health expenditure in 2010.[2]
• Note spending concentration: in 2012, 50% of compulsory health-insurance expenditure was directed to 3% of affiliates, described as people with long-term conditions.[2][45]
• Prioritise prevention because advanced chronic disease places a substantial burden on households, social-security and national-solidarity mechanisms, and the state; the existing expenditure trajectory is characterised as unsustainable without stronger prevention.[2][45]
• Budget operational measures and seek favourable government budget decisions, while recognising investment needs for pathway development, regional organisation, staffing and possible reimbursement packages for participating professionals.[30][35][34]
• Provide dedicated means and a specific budget for selected programme measures, although no amount, source breakdown or allocation is specified.[39]
• Mobilise potential operational or financial support from civil society, non-governmental organisations, local authorities, health-insurance bodies, the National Initiative for Human Development and international funds, without quantified contribution commitments.[38][39][46]
• Consider tobacco taxation and taxation of industries considered harmful to health as potential means to finance prevention and care; no tax rates, revenue projections or allocation rules are provided.[19]
• Address resource requirements for specialised cardiovascular and neurovascular centres, including capital investment, maintenance, technical platforms, medicines, laboratory services, training and specialised workforce capacity.[29][27][36]
• Manage the high costs associated with revascularisation, thrombolytic products, rehabilitation, palliative care, chronic ischaemic heart disease and advanced heart failure.[44][9][47][48][49][14]
• Account for implementation risks related to laboratory-testing costs, medicine costs, reliable thrombolytic supply and pharmacy constraints, while no monetary estimates are given.[26][28]
• Explore regulated, time-limited public-private arrangements where public capacity is inadequate, with contracts specifying service scope, duration and accessible pricing arrangements.[38]
• Recognise home-based palliative care as more accessible and less costly than hospital-based care, although no comparative cost estimate is supplied.[49]